• Home
  • About
  • Contact
  • Steve Walker
  • Subscriptions
    • Sample MondayMorning Newsletter January 11, 2016
Monday Morning
Skip to content
  • Home
  • About
  • Contact
  • Steve Walker
  • Subscriptions
    • Sample MondayMorning Newsletter January 11, 2016

Tag Archives: Oryzon Genomics SA

Europe bursts onto the biotech scene as Grifols’ Phase 2b/3 plasma replacement therapy works in Alzheimer’s patients. Buy, sell or hold?

Steve Walker    November 15, 2018 November 15, 2018    No Comments on Europe bursts onto the biotech scene as Grifols’ Phase 2b/3 plasma replacement therapy works in Alzheimer’s patients. Buy, sell or hold?

The News: A blood plasma replacement therapy from Spanish company Grifols SA (Barcelona) reduced cognitive decline by 61% in patients with moderate Alzheimer’s disease compared with placebo, Labiotech.eu reports. The… Read more »

Disease, Investment, Pharmaceuticals    Alzheimer Management by Albumin Replacement, Alzheimer’s Disease, Antonio Páez, Blood Plasma, BrainVectis SAS, Clinical Trials on Alzheimer’s Disease, French Institute for Health and Medical Research, Fundació ACE, Grifols SA, Labiotech.eu, Mercé Boada, Nathalie Cartier-Lacave, Oryzon Genomics SA, ThePharmaLetter, Victor Grifols Roura

Search The Site

Follow @MonMorningNews

Twitter

Tweets by MonMorningNews
Follow me on Blogarama

Facebook

Search The Site

More MondayMorning

  • Recent Posts
  • Most Commented
  • Most Viewed
  • US stock market has a subdued Thanksgiving week, but a slew of healthcare companies rocketed higher.
  • More Chinese medical companies choosing New York over Shanghai, Hong Kong for IPOs; but not always.
  • Health-sector IPO market cools off for Veterans Day breather; but pre-Thanksgiving deals ready to rock.
  • Health-sector IPO market cools off this week after torrid start to November.
    • Insys trial opens with tale of sales rep giving lap dance to doctor for fentanyl prescriptions. News organizations seize upon...
    • Voyager Therapeutics signs another neurodegenerative disease deal with AbbVie that screams “Buy this small cap now.”
    • Little known Czech biotech’s cell therapy greatly increases survival in ovarian cancer. Sotio’s potential breakthrough and another pipeline cancer candidate...
    • It’s time to reclassify schizophrenia as a neurologic disorder.
    Copyright 2018
    Ribosome by GalussoThemes.com
    Powered by WordPress